Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sholom Wacholder

Showing results (11-20 of 239) with videos related to

Pageof 24
Sort By:
Epidemiology (Cambridge, Mass.)|August 23, 2002
Validation studies: bias, efficiency, and exposure assessmentNilanjan Chatterjee, Sholom Wacholder
The Lancet. Oncology|November 15, 2011
Success of HPV vaccination is now a matter of coverageMark Schiffman, Sholom Wacholder
Journal of the National Cancer Institute|September 13, 2014
Talc use and ovarian cancer: epidemiology between a rock and a hard placeNicolas Wentzensen, Sholom Wacholder
Epidemiology (Cambridge, Mass.)|October 16, 2008
Observational data and clinical trials: narrowing the gap?Allen Wilcox, Sholom Wacholder
American Journal of Epidemiology|November 22, 2008
Invited commentary: efficient testing of gene-environment interactionNilanjan Chatterjee, Sholom Wacholder
The New England Journal of Medicine|April 3, 2009
From India to the world--a better way to prevent cervical cancerMark Schiffman, Sholom Wacholder
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 5, 2009
Control selection options for genome-wide association studies in cohortsSholom Wacholder, Melissa Rotunno
Trends in Molecular Medicine|June 18, 2002
One gene and one outcome? No wayStephen Chanock, Sholom Wacholder
Cancer Discovery|January 10, 2013
From differences in means between cases and controls to risk stratification: a business plan for biomarker developmentNicolas Wentzensen, Sholom Wacholder
American Journal of Epidemiology|November 22, 2008
Invited commentary: from genome-wide association studies to gene-environment-wide interaction studies--challenges and opportunitiesMuin J Khoury, Sholom Wacholder
Pageof 24

Showing results (11-20 of 239) with videos related to

Sort By:
Pageof 24
Epidemiology (Cambridge, Mass.)|August 23, 2002
Validation studies: bias, efficiency, and exposure assessmentNilanjan Chatterjee, Sholom Wacholder
The Lancet. Oncology|November 15, 2011
Success of HPV vaccination is now a matter of coverageMark Schiffman, Sholom Wacholder
Journal of the National Cancer Institute|September 13, 2014
Talc use and ovarian cancer: epidemiology between a rock and a hard placeNicolas Wentzensen, Sholom Wacholder
Epidemiology (Cambridge, Mass.)|October 16, 2008
Observational data and clinical trials: narrowing the gap?Allen Wilcox, Sholom Wacholder
American Journal of Epidemiology|November 22, 2008
Invited commentary: efficient testing of gene-environment interactionNilanjan Chatterjee, Sholom Wacholder
The New England Journal of Medicine|April 3, 2009
From India to the world--a better way to prevent cervical cancerMark Schiffman, Sholom Wacholder
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 5, 2009
Control selection options for genome-wide association studies in cohortsSholom Wacholder, Melissa Rotunno
Trends in Molecular Medicine|June 18, 2002
One gene and one outcome? No wayStephen Chanock, Sholom Wacholder
Cancer Discovery|January 10, 2013
From differences in means between cases and controls to risk stratification: a business plan for biomarker developmentNicolas Wentzensen, Sholom Wacholder
American Journal of Epidemiology|November 22, 2008
Invited commentary: from genome-wide association studies to gene-environment-wide interaction studies--challenges and opportunitiesMuin J Khoury, Sholom Wacholder
Pageof 24